Hispanic children with high-risk neuroblastoma had worse survival outcomes than other children with the disease despite receiving treatment on clinical trials with standardized protocols, according to study results.
Researchers observed the disparities even after controlling for disease-related factors.
The findings, scheduled for presentation at ASCO Annual Meeting, also showed poorer 5-year OS rates among those with public vs. private insurance.
“We acknowledge that simply describing disparities is not enough,” Puja J. Umaretiya, MD, clinical fellow in pediatric hematology/oncology